Table of contents
April 2004 Vol 4 No 4
In this issue
p243 | doi:10.1038/nrc1330
Research Highlights
Chromosome instability: All about E
p245 | doi:10.1038/nrc1327
Oncogenes: Taking the direct route
p246 | doi:10.1038/nrc1335
Web Watch
Bringing mice together
p246 | doi:10.1038/nrc1337
Oncogenes: Finding a PIG in a haystack
p247 | doi:10.1038/nrc1328
In brief
Oncogenes | Carcinogenesis | Immunotherapy | Tumorigenesis
p247 | doi:10.1038/nrc1333
Tumorigenesis: Influential partnership
p248 | doi:10.1038/nrc1324
Angiogenesis: A helping hand
p248 | doi:10.1038/nrc1326
Chemosensitivity: MUCking up cell death
p249 | doi:10.1038/nrc1325
Tumour suppressors: Self-restraint
p250 | doi:10.1038/nrc1332
Tumorigenesis: Hero or villain?
p250 | doi:10.1038/nrc1334
Prevention: Tea time
p251 | doi:10.1038/nrc1329
Trial Watch
Rapid development against slow growth | Antibiotics and oestrogens
p251 | doi:10.1038/nrc1336
Reviews
Microtubules as a target for anticancer drugs
Mary Ann Jordan & Leslie Wilson
p253 | doi:10.1038/nrc1317
Tracing the network connecting brca and fanconi anaemia proteins
Ashok R. Venkitaraman
p266 | doi:10.1038/nrc1321
The pathobiology of mucositis
Stephen T. Sonis
p277 | doi:10.1038/nrc1318
Molecular targets in pituitary tumours
Anthony P. Heaney & Shlomo Melmed
p285 | doi:10.1038/nrc1320
MGMT: its role in cancer aetiology and cancer therapeutics
Stanton L. Gerson
p296 | doi:10.1038/nrc1319
Perspectives
Opinion
Rules of evidence for cancer molecular-marker discovery and validation
David F. Ransohoff
p309 | doi:10.1038/nrc1322
Timeline
The evolution of thalidomide and its IMiD derivatives as anticancer agents
J. Blake Bartlett, Keith Dredge & Angus G. Dalgleish
p314 | doi:10.1038/nrc1323
